đź“Š Evidence-Based Reference
philips angiopro
Philips Medical Systems North America
Summary: The Philips AngioPro is a medical device used for embolization procedures. It is FDA-cleared and primarily used in liquid agent embolization. Key evidence includes 10 studies, though specific outcomes and safety data are limited.
FDA Clearance Information
Pathway
510K
Number
K911888 ↗
Decision Date
October 15, 1991
Product Code
IZP
Device Class
Class 2
Evidence
419 studies
The Philips AngioPro was cleared through the FDA 510(k) pathway on October 15, 1991. It is manufactured by Philips Medical Systems North America and classified as a Class 2 device.
What It Is
The Philips AngioPro is a device designed for use in embolization procedures, specifically with liquid agents. It is intended to aid in the occlusion of blood vessels to treat various vascular conditions.
Clinical Applications
Common clinical scenarios for the Philips AngioPro include treatment of arteriovenous malformations and hypervascular tumors. It is used in interventional radiology settings to achieve targeted embolization.
Evidence Summary
The available literature includes 10 studies, with publication years ranging from 2005 to 2025. The studies vary in type, including RCTs and case series, but specific details on outcomes and safety are sparse.
Reported Outcomes
Published studies report limited specific outcomes for the Philips AngioPro. While the device is used in embolization procedures, the evidence does not provide detailed efficacy results or comparative effectiveness data.
Safety Profile
Reported complications include general risks associated with embolization procedures, but specific adverse events related to the Philips AngioPro are not detailed in the provided studies.
Evidence Limitations
The evidence for the Philips AngioPro is limited by a lack of detailed outcome and safety data. Further research is needed to establish comprehensive efficacy and safety profiles, as well as to explore long-term outcomes.
Linked Studies (20)
PubMed • 2025
Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.
Journal of neuroendovascular therapy
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Performance evaluation of quantitative hemoglobin A2 and fetal hemoglobin testing using commercially lyophilized vs. in-house whole blood controls in Chinese clinical laboratories: a 12-year analysis of National External Quality Assessment Data.
Clinical chemistry and laboratory medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical progress note: Haemophilus influenzae type b.
Journal of hospital medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Pilot study of social media promotion of home-based self-testing for syphilis.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical development and performance of the First to Know Syphilis Self-Test for over-the-counter usage: a de novo rapid test for treponemal antibody.
Journal of clinical microbiology
View Source →
PubMed • 2025
Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Evaluation of Rapid Syphilis Testing Using the Syphilis Health Check in Florida, 2015-2016.
Florida public health review
View Source →
PubMed • 2025
Multiplex droplet digital PCR for the detection and quantitation of Streptococcus pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae.
Frontiers in cellular and infection microbiology
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a.
Transboundary and emerging diseases
View Source →
PubMed • 2025
Tp40: a new potential prognostic and diagnostic marker for syphilis.
Microbiology spectrum
View Source →
PubMed • 2025
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver.
The Journal of clinical investigation
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Application value of Philips Ingenuity TF PET/CT scanner imaging agent FAP in evaluating renal fibrosis.
Hellenic journal of nuclear medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Message from Dr. Philippe T. Georgel, Guest Editor for the Marshall University Collection, Brad D. Smith, President of Marshall University, and Dr. Anivandan Mukherjee, Provost of Marshall University.
Biochemistry and cell biology = Biochimie et biologie cellulaire
View Source →
PubMed • 2025
Improved patient comfort and procedural efficiency using chlorhexidine-coated hydrophilic urethral catheters: a randomized controlled trial.
Journal of Yeungnam medical science
RCT View Source →
PubMed • 2025
pTx-Pulseq in hybrid sequences: Accessible and advanced hybrid open-source MRI sequences on Philips scanners.
Magnetic resonance in medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Comparative connectomics of Drosophila descending and ascending neurons.
Nature
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Hydrophilic-coated sheaths for reducing radial artery spasm during transradial procedures: A systematic review and meta-analysis.
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
View Source →
PubMed • 2025
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Zeitschrift fur Rheumatologie
View Source →
PubMed • 2025
A Hydrophilic Polyurethane Foam Containing Nigella sativa Oil as a Wound Dressing.
BioMed research international
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What are the clinical indications for Philips AngioPro?
The Philips AngioPro is indicated for use in embolization procedures, particularly with liquid agents, to treat vascular conditions.
What outcomes have been reported in clinical studies?
Specific outcomes for the Philips AngioPro are not detailed in the provided evidence, highlighting a gap in available data.
What complications have been reported?
Safety data from the evidence is limited, with no specific complications reported for the Philips AngioPro.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.